Skip to content
A2030Assembly2021-2022 SessionSame asS649

End Medication Treatment Delays

Official title

“Relates to medication assisted treatment for substance use disorders”

Sponsor Linda RosenthalAD-67+11 co-sponsorsAffects Health
Status
Signed by Governor
Impact
7/10
Significant
Outcome
Signed into law

Bill progress

Signed into law

What's happening

This bill prohibits prior authorization requirements for certain medications used to treat substance use disorders in New York.

Why it matters

  1. Expands immediate access. By eliminating prior authorization for all forms of buprenorphine, methadone, and long-acting injectable naltrexone, the bill ensures that people seeking treatment for substance use disorders can get medication without delays that might otherwise lead to relapse or overdose.

  2. Standardizes care across insurance plans. The bill applies to Medicaid and managed care plans, as well as relevant public health provisions, reducing differences in access caused by insurance barriers and making evidence-based treatment more consistently available statewide.

  3. Aligns with clinical best practices. Requiring that prescriptions follow "generally accepted national professional guidelines" ensures that patients receive care based on the latest scientific evidence, rather than being subjected to administrative hurdles.

  4. Addresses stigma and administrative burden. Removing prior authorization for these medications helps combat the stigma that substance use disorder patients often face and reduces paperwork and delays for both patients and healthcare providers.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

End Medication Treatment Delays

Plain English, a few words. Used as the page title.

Sponsors

History

  1. Signed chap.720
  2. Delivered to governor
  3. Returned to assembly
  4. Passed senateVote 55–8
  5. 3rd reading cal.1294
  6. Substituted for S649A
  7. Referred to finance
  8. Delivered to senate
  9. Passed assembly
  10. Advanced to third reading cal.347
  11. Reported
  12. Reported referred to ways and means
Show 1 earlier action
  1. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S649Senate

End Prior Authorization for Treatment

Senate Floor Calendar · Sponsor Pete Harckham

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

2030

2021-2022 Regular Sessions

IN ASSEMBLY

January 14, 2021

Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN, SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on Health

AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (gg) to read as follows:

(gg) all buprenorphine products, methadone or long acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder. Such medication assisted treatment shall not be subject to any prior authorization mandate.

§ 2. Subdivision 26-b of section 364-j of the social services law, as added by section 4 of part B of chapter 69 of the laws of 2016, is amended to read as follows:

26-b. Managed care providers shall not require prior authorization for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the prescription is for a non-preferred or non-formulary form of the drug or as otherwise required by section 1927(k)(6) of the Social Security Act] any buprenorphine products, methadone or long acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.

§ 3. Subdivision 10 of section 273 of the public health law, as amended by section 7 of part GG of chapter 56 of the laws of 2020, is amended to read as follows:

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00371-02-1

A. 2030 2

10. Prior authorization shall not be required for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the prescription is for a non-preferred or non-formulary form of such drug as otherwise required by section 1927(k)(6) of the Social Security Act. Further, prior authorization shall not be required for] any buprenorphine products, methadone, [when used for opioid use disorder and administered or dispensed in an opioid treatment program] or long acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.

§ 4. This act shall take effect on the ninetieth day after it shall have become a law; provided, however, that the amendments to subdivision 26-b of section 364-j of the social services law made by section two of this act shall not affect the repeal of such section, and shall be deemed repealed therewith.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.